ClinicalTrials.gg
Not yet recruitingNCT07951411Updated Nov 20, 2026

Evaluating the Efficacy and Safety of SAL0167 Tablets at Different Doses in Participants With Hyperlipidemia.

A Phase 2 interventional study of SAL0167 Dose 1 and SAL0167 Dose 2 in Hyperlipidemia, sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd. · Phase 2, Interventional, and Treatment

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 96 studies in Hyperlipidemias with a site in China — 31 open to participants now, 39 under way, 7 of them phase 3. Hyperlipidemias · China.

Planned enrollment
29th of 80
240 · median 155
Started
2026
with 14 others
Phase 2
11 of 96
3 open now
Primary completion
2027-07
later than 24 of 38 live
Registered
96th of 96
by date
Lead sponsor
4 of 96
Shenzhen Salubris Pharmaceuticals Co., Ltd.

Among the 96 studies in Hyperlipidemias with a site in China, this one is the 29th largest by planned enrollment of the 80 interventional ones that give a count, is one of 15 that started in 2026, is one of 11 in phase 2, reaches primary completion later than 24 of the 38 other live ones, and was the 96th registered.

Hyperlipidemias

864 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

31 of the 96 studies in Hyperlipidemias with a site in China are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 66 Hyperlipidemias studies recruiting now, 26 (39%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 96 studies in Hyperlipidemias with a site in China, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled, multicenter phase II clinical trial. The purpose of this study is to evaluate the efficacy and safety of SAL0167, an oral PCSK9 inhibitor, in lowering low-density lipoprotein cholesterol (LDL-C) in participants with hyperlipidemia. Participants will be randomized 1:1:1:1 to receive low-dose SAL0167, medium-dose SAL0167, high-dose SAL0167, or placebo for a treatment period of 8 weeks.

Read the detailed description

The duration of the study for each participant is approximately 16 weeks, including a screening period of up to 2 weeks, a lead-in period of at least 4 weeks, a double-blind treatment period of 8 weeks, and a safety follow-up period of 2 weeks. We plan enrolled 240 participants with hyperlipidemia, both male and female. The participants were classified according to the ASCVD risk levels as per the "Chinese Guidelines for Lipid Management (2023)", and their LDL-C levels did not reach the treatment targets.

Qualified participants will enter the lead-in period. At the end of the lead-in period, the compliance will be re-evaluated. Participants with a compliance of 80% to 120% and meeting the criteria will be randomly assigned in a 1:1:1:1 ratio to the low-dose SAL0167, medium-dose SAL0167, high-dose SAL0167, or placebo group. The randomly assigned trial participants will then enter an 8-week double-blind treatment period. After the treatment is completed, a 2-week safety follow-up period will follow.

03

Conditions studied

  • Hyperlipidemia

Browse trials for

Keywords

  • Hyperlipidemia
  • double-blind
  • LDL-C
  • safety
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily participate in the trial and be able to understand and sign the Form (ICF).
  • Sign the ICF when the age is ≥ 18 years old, regardless of gender.
  • should be within the range of 18 kg/m2 to 40 kg/m2, with men weighing ≥ 50.0 kg and women weighing ≥ 45.0 kg.
  • According to the "Chinese Guidelines for Lipid Management (2023)", the ASCVD risk level should be classified and LDL-C should not meet the standard.
  • Fasting LDL-C should be \< 4.9 mmol/L.
  • Fasting triglycerides (TG) should be ≤ 5.6 mmol/L.
  • During the lead-in period, the medication compliance rate of the test drugs between 80% and 120%.

Exclusion criteria

Exclusion Criteria:

  • Have used drugs with weight loss effects or undergone surgeries that cause unstable weight within the past 2 months.
  • Have been using systemic continuously or repeatedly for more than 3 months.
  • Have a disease that significantly affects lipid levels and is uncontrollable.
  • Have hyperthyroidism or hypothyroidism that is uncontrollable.
  • Have type 1 diabetes or poorly controlled type 2 diabetes.
  • Participants had one of the following conditions a) Positive surface antigen (HBsAg) and/or positive antibody. b) Positive antibody and/or syphilis spirochete antibody test results. c) \< 45 mL/min/1.73m2. d) Creatine phosphokinase (CK) > 3×.
  • Poorly controlled hypertension.
  • -defined grade Ⅲ-Ⅳheart failure, or have prolonged .
  • Have poorly controlled severe arrhythmia within the past 3 months, such as recurrent and highly symptomatic ventricular tachycardia, rapid ventricular reactivity atrial fibrillation or supraventricular tachycardia, etc.
  • Have myocardial infarction, unstable angina pectoris, percutaneous coronary intervention, coronary artery bypass grafting, severe deep vein thrombosis or pulmonary embolism or cerebrovascular accident within the past 3 months; or plan to undergo cardiac surgery or cardiac revascularization during the study period.
  • Have had malignant tumors within the past 5 years.
  • Have undergone any major organ transplantation, such as lung, liver, heart, bone marrow, kidney.
  • Have participated in or are participating in other clinical studies and received drugs or devices within 5 half-lives before the screening and first administration of this study.
  • Have undergone major surgery (non-ambulatory surgery) within the past 3 months or plan to undergo major surgery during the study period.
  • Have undergone lipoprotein apheresis within the past 3 months or plan to undergo this treatment during the study period.
  • Have a history of alcohol abuse within the past 6 months.
  • Are pregnant (positive pregnancy test for women of childbearing age) or lactating.
  • The participant and their spouse or partner have a pregnancy plan, or do not agree to adopt an acceptable at least one effective method during the study period and after the last administration.
  • Have an allergy to the active ingredient of SAL0167 or any .
  • Have severe cognitive dysfunction and cannot cooperate with medication or follow-up.
  • The investigator considers the participant unsuitable for the clinical trial.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    test group 1

    SAL0167 Dose 1

    Drug: SAL0167 Dose 1

  • Experimental
    test group 2

    SAL0167 Dose 2

    Drug: SAL0167 Dose 2

  • Experimental
    test group 3

    SAL0167 Dose 3

    Drug: SAL0167 Dose 3

  • Placebo comparator
    Reference Group

    Placebo

    Drug: placebo

Interventions

  • DrugSAL0167 Dose 1

    SAL0167 Dose 1

  • DrugSAL0167 Dose 2

    SAL0167 Dose 2

  • DrugSAL0167 Dose 3

    SAL0167 Dose 3

  • Drugplacebo

    placebo

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)

    Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 8

    Time frame: to Week 8

Secondary outcomes

  1. Percentage of Participants With LDL-C Value at Goal

    Percentage of Participants With LDL-C Value at Goal at Week 8

    Time frame: at Week 8

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jul 2027, 6 months later.

Of 30 phase 2 interventional studies under Hyperlipidemias, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 27. This study's planned 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2026
First posted
Nov 20, 2026
StartEst.
Dec 31, 2026
Primary completionEst.
Jul 30, 2027
CompletionEst.
Jul 30, 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07951411
Responsible party
Sponsor
First posted
Nov 20, 2026
Start date
Dec 31, 2026 (estimated)
Primary completion
Jul 30, 2027 (estimated)
Completion
Jul 30, 2027 (estimated)
Last update
Nov 20, 2026

Study contacts

Jianping Li, M.D
Contact
13521531013@163.com
13521531013
Jianping Li, M.D
principal investigator · Peking University First Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion